Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role of venetoclax in combination with intensive chemotherapy in fitter patients with AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Moujalled, Donia M., Brown, Fiona C., Chua, Chong Chyn, Dengler, Michael A., Pomilio, Giovanna, Anstee, Natasha S., Litalien, Veronique, Thompson, Ella, Morley, Thomas, MacRaild, Sarah, Tiong, Ing S., Morris, Rhiannon, Dun, Karen, Zordan, Adrian, Shah, Jaynish, Banquet, Sebastien, Halilovic, Ensar, Morris, Erick, Herold, Marco J., Lessene, Guillaume, Adams, Jerry M., Huang, David C. S., Roberts, Andrew W., Blombery, Piers, Wei, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651776/
https://www.ncbi.nlm.nih.gov/pubmed/36219880
http://dx.doi.org/10.1182/blood.2022016090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651776/
https://www.ncbi.nlm.nih.gov/pubmed/36219880
http://dx.doi.org/10.1182/blood.2022016090

Ejemplares similares